Favourable behavioural actions of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist antipsychotic candidate

被引：0
|
作者：
Gyertyan, I. [1 ]
Kiss, B. [1 ]
Saghy, K. [1 ]
Laszy, J. [1 ]
Szabo, G. [1 ]
Agai-Csongor, E. [1 ]
Domany, G. [1 ]
Tihanyi, K. [1 ]
Szombathelyi, Z. [1 ]
机构：
[1] Pharmacol & Drug Safety Res, Budapest, Hungary
来源：
BEHAVIOURAL PHARMACOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号：
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要：
引用
收藏
页码：S12 / S13
页数：2
相关论文
共 50 条
  • [31] Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys
    Paul W. Czoty
    H. Donald Gage
    Pradeep K. Garg
    Sudha Garg
    Michael A. Nader
    Psychopharmacology, 2014, 231 : 613 - 619
  • [32] Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys
    Czoty, Paul W.
    Gage, H. Donald
    Garg, Pradeep K.
    Garg, Sudha
    Nader, Michael A.
    PSYCHOPHARMACOLOGY, 2014, 231 (03) : 613 - 619
  • [33] Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor
    Wood, MD
    Boyfield, I
    Nash, DJ
    Jewitt, FR
    Avenell, KY
    Riley, GJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 407 (1-2) : 47 - 51
  • [34] (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions
    Jin, GZ
    Zhu, ZT
    Fu, Y
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (01) : 4 - 7
  • [35] The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia
    Watson, David J. G.
    King, Madeleine V.
    Gyertyan, Istvan
    Kiss, Bela
    Adham, Nika
    Fone, Kevin C. F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (02) : 208 - 224
  • [36] The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors
    Wicke, K
    Garcia-Ladona, J
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 424 (02) : 85 - 90
  • [37] Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist
    Chien, Ellen Y. T.
    Liu, Wei
    Zhao, Qiang
    Katritch, Vsevolod
    Han, Gye Won
    Hanson, Michael A.
    Shi, Lei
    Newman, Amy Hauck
    Javitch, Jonathan A.
    Cherezov, Vadim
    Stevens, Raymond C.
    SCIENCE, 2010, 330 (6007) : 1091 - 1095
  • [38] F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: Influence on neuronal firing and neurotransmitter release
    Assie, Marie-Bernadette
    Mnie-Filali, Ouissame
    Ravailhe, Veronique
    Benas, Christelle
    Marien, Marc
    Betry, Cecile
    Zimmer, Luc
    Haddjeri, Nasser
    Newman-Tancredi, Adrian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 607 (1-3) : 74 - 83
  • [39] Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA
    D'Souza, U
    McGuffin, P
    Buckland, PR
    NEUROPHARMACOLOGY, 1997, 36 (11-12) : 1689 - 1696
  • [40] The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure
    Holmes, Ian P.
    Blunt, Richard J.
    Lorthioir, Olivier E.
    Blowers, Stephen M.
    Gribble, Andy
    Payne, Andrew H.
    Stansfield, Ian G.
    Wood, Martyn
    Woollard, Patrick M.
    Reavill, Charlie
    Howes, Claire M.
    Micheli, Fabrizio
    Di Fabio, Romano
    Donati, Daniele
    Terreni, Silvia
    Hamprecht, Dieter
    Arista, Luca
    Worby, Angela
    Watson, Steve P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (06) : 2013 - 2016
12345